Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.79 USD
-0.02 (-1.10%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.77 -0.02 (-1.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
FBIO 1.79 -0.02(-1.10%)
Will FBIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FBIO
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
FBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
Other News for FBIO
Avenue Therapeutics Announces Reverse Stock Split
12 Health Care Stocks Moving In Wednesday's After-Market Session
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Fortress Biotech price target raised by $14 at H.C. Wainwright, here's why
Buy Rating Affirmed: A Promising Outlook for Fortress Biotech Amid Upcoming Regulatory Milestones and Strategic Investments